Evidence map›Paper›PMID 35458440›Full record

ArticleViruses2022

Prognosis of Indolent Adult T-Cell Leukemia/Lymphoma.

Takuro Kameda, Kotaro Shide, Yuki Tahira, Masaaki Sekine, Seiichi Sato, Junzo Ishizaki, Masanori Takeuchi, Keiichi Akizuki, Ayako Kamiunten, Haruko Shimoda and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. IncreasedInternational journal of molecular sciences · 2024
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Takuro KamedaDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan.ORCID 0000-0003-0100-1710
Kotaro ShideDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan.ORCID 0000-0002-0046-3254
Yuki TahiraDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan.
Masaaki SekineDepartment of Internal Medicine, Koga General Hospital, Miyazaki 880-0041, Japan.
Seiichi SatoDepartment of Internal Medicine, Miyakonojo Medical Center, Miyakonojo 880-8510, Japan.
Junzo IshizakiDepartment of Internal Medicine, Aisenkai Nichinan Hospital, Nichinan 887-0034, Japan.
Masanori TakeuchiDepartment of Internal Medicine, Aisenkai Nichinan Hospital, Nichinan 887-0034, Japan.
Keiichi AkizukiDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan.ORCID 0000-0003-0031-3456
Ayako KamiuntenDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan.
Haruko ShimodaDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan.
Takanori ToyamaDepartment of Internal Medicine, Miyazaki Prefectural Nobeoka Hospital, Nobeoka 882-0835, Japan.
Kouichi MaedaDepartment of Internal Medicine, Miyakonojo Medical Center, Miyakonojo 880-8510, Japan.
Kiyoshi YamashitaDepartment of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki 889-1692, Japan.
Noriaki KawanoDepartment of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki 889-1692, Japan.
Hiroshi KawanoDepartment of Internal Medicine, Koga General Hospital, Miyazaki 880-0041, Japan.
Tomonori HidakaDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan.
Hideki YamaguchiDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan.
Yoko KubukiDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan.
Akira KitanakaDepartment of Laboratory Medicine, Kawasaki Medical School, Kurashiki 701-0192, Japan.
Hitoshi MatsuokaDepartment of Internal Medicine, Koga General Hospital, Miyazaki 880-0041, Japan.
Kazuya ShimodaDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki 889-1692, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A retrospective chart survey of the clinical features of indolent adult T-cell leukemia/lymphoma (ATL) was conducted in the Miyazaki Prefecture, Japan. This study enrolled 24 smoldering-type ATLs, 10 favorable chronic-type ATLs, and 20 unfavorable chronic-type ATLs diagnosed between 2010 and 2018. Among them, 4, 3, and 10 progressed to acute-type ATLs during their clinical course. The median survival time (MST) in smoldering-type ATL and favorable chronic-type ATL was not reached, and their 4-year overall survival (OS) was 73% and 79%, respectively. Compared with this, the prognosis of unfavorable chronic-type ATL was poor. Its MST was 3.32 years, and the 4-year OS was 46% (p = 0.0095). In addition to the three features that determine the unfavorable characteristics of chronic-type ATL, namely, increased lactate dehydrogenase, increased blood urea nitrogen, and decreased albumin, the high-risk category by the indolent ATL-Prognostic Index, which was defined by an increment of soluble interleukin-2 receptor (sIL2-R) of >6000 U/mL, could explain the poor prognosis in indolent ATL patients. The level of sIL-2R might be an indicator of the initiation of therapy for indolent ATL.

Indexed as

Leukemia-Lymphoma, Adult T-CellLymphomaAdultHumansJapanPrognosisRetrospective Studiesadult T-cell leukemia/lymphomachronic-typeiATL-PIsmoldering-type

Identifiers

PMID35458440
PMCPMC9030133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.